- The 2023 American Society of Clinical Oncology (ASCO) will see a return of in-person attendance with 40,000 people already registered
- Presentations are set from some of the biotech sector’s most notable names
- The ASCO annual meeting will be held in Chicago from June 2 to 6, 2023
- Invitae Corp. (NVTA) opened trading at C$1.49 and Oncolytics Biotech Inc. (ONC) opened trading at C$2.85 per share
Next week, top health care firms will converge or the biggest cancer conference in the world.
The 2023 American Society of Clinical Oncology (ASCO) will see a return of in-person attendance with 40,000 people already registered.
Presentations are set from some of the biotech sector’s most notable names. Invitae (NYSE:NVTA), a leading medical genetics company, announced on Friday that nine studies will be presented.
The new research insights highlight innovations in genetic testing in a variety of clinical settings, population groups and cancer types, and reinforce the need to reduce barriers to genetic services to help patients receive the most effective care and monitoring.
Oncolytics Biotech (NASDAQ:ONCY / TSX:ONC) announced that positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer will be presented at ASCO.
The BRACELET-1 (BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 and Paclitaxel) is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement with Pfizer Inc. (NYSE:PFE) and Merck KGaA, Darmstadt, Germany.
The ASCO annual meeting will be held in Chicago from June 2 to 6, 2023. To find out more about Oncolytics’ study that will be featured at the event, click here.
Invitae Corp. (NVTA) opened trading at C$1.49 and Oncolytics Biotech Inc. (ONC) opened trading at C$2.85 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
